Anna Eshoo: “I think there--it continually is a reexamination, Madam Chairwoman.”

It is stunning to me that someone pays for something, they don't get it, but the person or the entity they paid it to still gets to keep it.

I see, as I expressed to you when we spoke, a disconnect between CMS, the FDA, and the VA on new treatments for mild Alzheimer's.

This is, as you said and have said many times, this is a devastating disease, and I don't think this can be treated as 17 months of a little additional hope.

I want to ask you if you will consider STAs and if you will commit to providing the public transparency that is really due because this is a huge issue?